A Phase IV Open-label Multicentre International Pilot Study of 4-week Treatment With Sofosbuvir (400 mg) Plus Glecaprevir/Pibrentasvir (300mg/120mg) in Chronic HCV Treatment naïve Patients With Early Liver Disease
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STRIVE-4
Most Recent Events
- 04 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2026.
- 04 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2026.
- 10 Dec 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Feb 2024.